Apellis Pharmaceuticals (STU:1JK) LT-Debt-to-Total-Asset : 0.51 (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Apellis Pharmaceuticals LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Apellis Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.51.

Apellis Pharmaceuticals's long-term debt to total assets ratio increased from Sep. 2023 (0.13) to Sep. 2024 (0.51). It may suggest that Apellis Pharmaceuticals is progressively becoming more dependent on debt to grow their business.

Apellis Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

The historical data trend for Apellis Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apellis Pharmaceuticals LT-Debt-to-Total-Asset Chart

Apellis Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.40

0.39

0.23

0.14

0.13

Apellis Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.13	0.13	0.12	0.52	0.51

Apellis Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Apellis Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	95.815	/	723.265
	=	0.13

Apellis Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	417.754	/	812.581
	=	0.51

Apellis Pharmaceuticals (STU:1JK) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Apellis Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Apellis Pharmaceuticals's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Apellis Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apellis Pharmaceuticals Inc (STU:1JK) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

APLS:USA

Address

100 Fifth Avenue, Waltham, MA, USA, 02451

Website

https://www.apellis.com

Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.

Apellis Pharmaceuticals Headlines

No Headlines